Bayesian selective response-adaptive design using the historical control. by Kim, Mi-Ok et al.
UCSF
UC San Francisco Previously Published Works
Title
Bayesian selective response-adaptive design using the historical control.
Permalink
https://escholarship.org/uc/item/7ws9z50v
Journal
Statistics in medicine, 37(26)
ISSN
0277-6715
Authors
Kim, Mi-Ok
Harun, Nusrat
Liu, Chunyan
et al.
Publication Date
2018-11-01
DOI
10.1002/sim.7836
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
Received: 12 May 2017 Revised: 4 May 2018 Accepted: 4 May 2018
DOI: 10.1002/sim.7836
RE S EARCH ART I C L E
Bayesian selective response-adaptive design using the
historical control
Mi-Ok Kim1,4 Nusrat Harun1 Chunyan Liu2 Jane C. Khoury2 Joseph P. Broderick3
1UCSF Helen Diller Family
Comprehensive Cancer Center, San
Francisco, California, USA
2Cincinnati Children's Hospital Medical
Center, Cincinnati, Ohio, USA
3Department of Neurology and
Rehabilitation Medicine,University of
Cincinnati College of Medicine,
Cincinnati, Ohio, USA
4Department of Epidemiology and
Biostatistics, University of California San
Francisco, San Francisco, California, USA
Correspondence
Mi-Ok Kim, UCSF Helen Diller Family
Comprehensive Cancer Center, San
Francisco, CA 94143-0981, USA.
Email: Miok.Kim@ucsf.edu
High quality historical control data, if incorporated, may reduce sample size,
trial cost, and duration. A too optimistic use of the data, however, may result
in bias under prior-data conflict. Motivated by well-publicized two-arm com-
parative trials in stroke, we propose a Bayesian design that both adaptively
incorporates historical control data and selectively adapt the treatment alloca-
tion ratios within an ongoing trial responsively to the relative treatment effects.
The proposed design differs from existing designs that borrow from historical
controls. As opposed to reducing the number of subjects assigned to the con-
trol arm blindly, this design does so adaptively to the relative treatment effects
only if evaluation of cumulated current trial data combined with the historical
control suggests the superiority of the intervention arm. We used the effective
historical sample size approach to quantify borrowed information on the con-
trol arm and modified the treatment allocation rules of the doubly adaptive
biased coin design to incorporate the quantity. The modified allocation rules
were then implemented under the Bayesian frameworkwith commensurate pri-
ors addressing prior-data conflict. Trials were also more frequently concluded
earlier in line with the underlying truth, reducing trial cost, and duration and
yielded parameter estimates with smaller standard errors.
KEYWORDS
Bayesian design with commensurate priors, borrowing on the historical control data, doubly
adaptive biased coin design, response-adaptive design
1 INTRODUCTION
Historical data have conventionally been used for establishing parameters needed for designing a proposed clinical trial
but have rarely been used for evaluating the scientific aims. High quality historical control data exist, for example, when
the treatment of intervention arm of a successful historical trial serves as the treatment in the control arm of a pro-
posed trial, as illustrated in a published stroke trial described later. Since a seminal article by Pocock,1 several researchers
have proposed combining historical and concurrent controls in analysis2-4 by discounting historical data to account for
between-trial heterogeneity. Despite careful selection of historical trials, study design, conduct, or subject population
may differ so past information may not be relevant for the proposed trial. Bayesian designs were introduced to address
such prior-data conflict by data adaptively determining the degree of borrowing on the control arm using power priors,5-7
commensurate priors,8-10 or meta-analytic-predictive priors.11 All this work, however, focused on reducing the number of
study subjects assigned to the control group without taking into account the true relative treatment effects. This meant
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assigning more trial participants to the intervention arm even if the intervention arm was inferior, which in many cases
is not desirable, as the safety of the intervention arm has not been well established. In our work, we propose a Bayesian
design that adaptively incorporates historical control data while selectively adapting the allocation ratios in response to
the true response rates only when evaluation of the combined current trial and historical control data suggests superiority
of the intervention arm. The proposed design, therefore, aims to reduce the number of subjects treated with the control
arm only when the intervention arm is truly superior. In this sense, the proposed design is doubly adaptive, adaptive to
both the prior-data conflict and to the true response rates.
The proposed design combines a response-adaptive randomization scheme selected from the literature with a Bayesian
design that adaptively borrows on the historical control. We specifically combine the response-adaptive randomization
scheme used in the doubly adaptive biased coin design (DBCD)12 and a Bayesian design using commensurate priors.10
These choices have some advantages; the DBCD randomization is known to perform less variably compared to sequential
maximum likelihood estimate procedures.13 Nevertheless, the choices are largely arbitrary and other response-adaptive
randomization schemes including Bayesian designs borrowing on the historical control can be considered.
From the response-adaptive randomization point of view, the proposed design may better realize the purported thera-
peutic advantages of adaptive randomization in a two-arm comparative trial. Compared with conventional fixed designs,
response-adaptive randomization is believed to improve the trial participants' outcomes by skewing allocation probabili-
ties in favor of better performing arms at the time of randomization and, hence, are ethically superior and desirable.14,15
Apart from controversies over the ethics of adaptive randomization,16 the purported therapeutic advantages have also
been questioned: the advantages were reported to exist only when the true relative effects differ greatly, and consequently,
the purported therapeutic advantages were rarely realized in practice.17-19 The advantages, if they exist, also disappeared
when trials were allowed to stop early for efficacy or futility.17 We shall evaluate whether the proposed Bayesian design
overcomes these shortcomings. Comparative two-arm trials typically include interim analyses for early stopping for effi-
cacy or futility, and the primary endpoints are frequently observed after a defined time delay. The challenge of delayed
responses has been addressed by utilizing correlated short-term endpoints, and varying degree of efficiency gains by the
strength of the correlation was reported (see the work of Kim et al20 for example). Huang et al21 proposed a Bayesian joint
modeling approach utilizing short-term outcomes, which we adapted here. We also accommodated interim analyses in
the proposed two-arm trial design.
This paper is organized as follows. Section 2 describes a published stroke trial for a motivating study. The proposed new
Bayesian design will be introduced in Section 3. Empirical study results will be presented in Section 4, and a summary
and discussion will be presented in Section 5.
2 CASE STUDY
Two well-known stroke trials, the National Institute of Neurological Disorders and Stroke t-PA Stroke Study (NINDS)
and the Interventional Management of Stroke (IMS) III trial, are used to illustrate the proposed design. The NINDS trial
demonstrated the efficacy of recombinant tissue plasminogen activator (rt-PA) compared with a placebo control.22 Small
randomized trial23 and two single-group trials24,25 reported improved efficacy of intravenous rt-PA (IV rt-PA) followed by
endovascular therapy. Based on this preliminary work, the IMS III trial evaluated the efficacy of combining IV rt-PA with
intra-arterial recanalization endovascular therapy against the IV rt-PA alone control in moderate/severe stroke patients.
The NINDS trial included 126 subjects withmoderate and 56 subjects with severe stroke (severity at baseline as measured
by the NIH Stroke Scale [NIHSS]) treated with IV rt-PA alone who would have satisfied the eligibility criteria of the IMS
III. Both trials were similar in the subject population and study conduct. We refer to the work of Khatri et al26 for details.
The primary outcome in the IMS III trial was a successful recovery assessed at 90 days post stroke defined by the mod-
ified Rankin Score (0-2 on a 6-point scale). The trial targeted to enroll a maximum of 900 participants with three interim
analyses planned when respectively 25%, 50%, and 75% of the target sample had the primary outcome observed. The par-
ticipants were randomized in a 2:1 ratio to favor the combined therapy. The O'Brien and Fleming spending rules27 were
used to determine the efficacy boundaries of the interim analyses to ensure the overall type I error rate at 5%. The cri-
terion for early stopping for futility was prespecified as having less than 20% conditional power under the alternative
hypothesis. The IMS III trial was designed to have 80% power detecting overall 10% absolute difference in the primary
outcome (assuming 40% for control and 50% for the intervention arm). The trial stopped for futility after enrolling
656 participants. A post hoc analysis by stroke severity observed that the intervention arm had a lower response rate in
the moderate stroke stratum by 1.0% but a higher response by 6.8% in the severe stroke stratum.
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The post hoc analysis and the preceding NINDS rt-PA trial motivated the proposed design. The proposed design is
stratified by baseline stroke severity to allow independent adaptation of treatment allocation and evaluation of the relative
effect of the combined approach within each stratum. The fixed 2:1 ratio in the original trial also suggests that the new
design incorporating the NINDS trial data to reduce the numbers of subjects needed in the concurrent control arm if the
intervention arm is truly superior represents a potentially superior approach.
The IMS III stroke trial exhibits common features of two-arm comparative trials, which can be challenging to accom-
modate for a response-adaptive trial. The primary outcome of a successful recovery assessed at 90 days post stroke was
not completely observed in all previously enrolled study subjects when a new subject was available for randomization
and allocation probabilities needed to be updated. Fifty percent of the time, 20 or more new subjects in the moderate
stratum and 6 or more new subjects in the severe stroke stratum, had been enrolled before the primary outcome was
completely observed in previously randomized subjects. Randomization can be adapted based on complete data only. The
complete data only application, however, was shown reducing the efficiency of adaptive randomization.20,21 Clinical trials
commonly collect many short-term outcomes, some of which are predictive of the long-term outcomes. Approaches that
mitigate the impact of the delay by utilizing observed predictors of the delayed outcome20,21 have been proposed. In the
IMS III stroke trial subjectswere assessed at 24 hours post stroke for severity of their condition, an improvement (decrease)
of 4 points or more from the baseline assessment measured on the NIHSS score was predictive of a successful recovery at
90 days post stroke.We utilized this short-term predictor information similarly as the joint likelihood approach proposed21
to mitigate the impact of the delayed primary outcome.
3 METHODS
The proposed design incorporates the DBCD response-adaptive randomization scheme12 in a Bayesian design using com-
mensurate priors.10 It uses both the cumulating concurrent trial data and the historical control data to estimate the
expected values of the primary outcome in each treatment group and updates allocation probabilities only if the primary
outcome estimates suggest superiority of the intervention arm. We modify the treatment allocation probability computa-
tion to account for the additional information provided to the control group by the historical data. The effective historical
sample size (EHSS) approach10 is used to quantify the borrowed historical data information in the control arm. For clarity
of exposition, we first describe the likelihood for the delayed primary endpoint that incorporates the short-term predic-
tor outcome. We then describe how the commensurate priors and the effective sample size computation are adapted for
the proposed design. Lastly, we describe how to modify the allocation probability computation to selectively adapt to the
response and to account for the additional historical control data.
3.1 The joint outcomemodel
We use the trial context of the motivating example. We let Ti be the treatment indicator with Ti = 1 for the intervention
arm, Xi denote the strata, Zi denote the short-term predictor, and Yi denote the primary endpoint. We assume Yi may
not be observable immediately, whereas Xi and Zi are. In the motivating example, the primary endpoint of a successful
recovery was determined at 90 days post stroke if a study subject survived beyond the assessment or was determined as
a failure whenever subjects died within 90 days. In order to account for the delayed response, we let Ui denote times to
death and are censored at some fixed time u0 (post 90 days assessment time) with 𝛿i = 1 denoting observed deaths within
the time u0. Given (Xi,Ti,Zi) = (x, t, z), we assume Ui are independent and identically distributed with the hazard and
survival functions respectively denoted by h(u|x, t, z) and S(u|x, t, z). We further assume the following models:
Zi|Xi = x,Ti = t ∼ i.i.d.Bernoulli(𝛼(x, t)) ,
Yi|Xi = x,Ti = t,Zi = z, 𝛿i = 0 ∼ i.i.d.Bernoulli(𝛽(x, t, z)), (1)
where 𝛼(x, t) = P(Zi = 1|Xi = x,Ti = t) and 𝛽(x, t, z) = P(Yi = 1|Xi = x,Ti = t,Zi = z, 𝛿i = 0). Then, the probability
of a successful recovery of the treatment arm t in the stroke stratum x is given by
𝜇(x, t) =
∑
z
P(Z = z)P(Y = 1&U > u0|X = x,T = t,Z = z) (2)
=
∑
z
P(Z = z)P(U > u0|X = x,T = t,Z = z)P(Y = 1|X = x,T = t,Z = z,U > u0)
= 𝛼(x, t)S(u0|x, t, z = 1)𝛽(x, t, z = 1) + {1 − 𝛼(x, t)}S(u0|x, t, z = 0)𝛽(x, t, z = 0) .
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When themth subject is enrolled and ready for treatment assignment, observations would be incomplete in the previ-
ously enrolled subjects who are alive (𝛿i = 0) but have not yet survived to the primary assessment time u0. We treat the
unobserved (Ui, 𝛿i,Yi) as missing at random and do single imputation.We suppose that a maximumN number of subjects
would enroll in the current trial sequentially with d1, … , dN denoting the delayed entry times since the inception of the
trial. When dm − di denote the observed survival time censored at the entry of themth subject, we impute using the pos-
terior distribution conditioning on dm − di. We let (ui(m), 𝛿i(m), yi(m)) denote the imputed values forUi > dm − di or the
observed values for Ui ≤ dm − di. When 𝜽 denotes a vector of parameters involved with 𝛼(x, t), 𝛽(x, t, z), and h(u|x, t, z)
for the current trial, we have the following log-likelihood for 𝜽 from the concurrent trial subject i:
li(m)(𝜽) = zi log
{
𝛼(xi, ti)
1 − 𝛼(xi, ti)
}
+ log{1 − 𝛼(xi, ti)} (3)
+ 𝛿i(m) log h(ui(m)|xi, ti, zi) + log S(ui(m)|xi, ti, zi)
+ (1 − 𝛿i(m))
[
𝑦i(m) log
{
𝛽(xi, zi, ti)
1 − 𝛽(xi, z i, ti)
}
+ log{1 − 𝛽(xi, z i, ti)}
]
.
When (m) denotes the current trial data available at the time of treatment allocation of the mth subject, the likelihood
for 𝜽 is given by L(𝜽|(m)) = exp{∑m−1i=1 li(m)(𝜽)}.
We assume the same modeling assumptions also hold for the historical control data 0 of sample size N0. When 𝜽0
denotes the vector of the parameters involved with the historical control models, l𝑗(N0)(𝜽0) respectively denotes the con-
trol group log-likelihood from the historical trial subject j with (uj(N0), 𝛿j(N0), yi(N0)) denoting the completely observed
observation. Then, the likelihood for 𝜽0 is given by: L0(𝜽0|0) = exp{∑N0i=1 li(N0)(𝜽0)}. Then, the likelihood that combines
both the current trial and the historical control data is given by
L(𝜽,𝜽0|(m),0) = L(𝜽|(m))L0(𝜽0|0) .
We extend the commensurate priors10 to this multivariate setting. We assume 𝜽 and 𝜽0 are 𝜈−variate vectors with the
elements denoted respectively by 𝜽(l) and 𝜽0(l ) for l = 1, … , 𝜈. The priors of 𝜽 given 𝜽0 is defined as follows:
𝑝(𝜽|𝜽0,𝝎) = 𝜈∏
l=1
𝜙(𝜽l|𝜽0(l), 𝜏l)𝜋(𝜏l|𝝎) , (4)
where 𝜙(·|𝜽0(l ), 𝜏 l) are the probability density functions of Gaussian random variables with the mean 𝜽0(l ) and the vari-
ance 1∕𝜏 l, l = 1, … , 𝜈. The amount of commensurability for cross-study borrowing is controlled by the hyperparameters
𝜏 l, and the priors 𝜋(𝜏 l|𝝎) are given by “spike and slab” distributions28 that are mixture of uniform distributions and
point probability distributions (see the Appendix for details). This prior has shown desirable bias-variance trade-offs for
estimating concurrent effects in a univariate setting where a time-to-event outcome model was similarly assumed.10
3.2 Effective historical sample size
We compute EHSS following the work of Hobbs et al.10 Under the sequential enrollment considered here, when themth
study subject is ready for treatment assignment, the posterior distribution of 𝜽 based only on the current trial data is
q∗(𝜽|(m)) ∝ 𝑝(𝜽)L(𝜽|(m)), (5)
where p(𝜽) is a noninformative prior distribution for 𝜽. In contrast, the posterior distribution of 𝜽 based on both the
historical and current trial data is
q(𝜽|(m),0) ∝ L(𝜽|(m))∫
𝜽0
𝑝(𝜽|𝜽0,𝝎)𝑝0(𝜽0)L0(𝜽0|0)d𝜽0 , (6)
where p0(𝜽0) similarly denotes a noninformative prior distribution for 𝜽0. We let ∗x ((m)) and x(0,(m)) be the pos-
terior precisions of 𝜇x(t = 0), x = 0, 1, the control arm response rate estimates by strata, drawn from the posterior
distributions (5) and (6), respectively. We also let n(m)(x, t) denote the numbers of subjects previously assigned to the treat-
ment arm t in the stratum x at the timewhen themth subject is ready for treatment assignment. Given a linear relationship
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between the sample size and the posterior precisions, the EHSS in the stroke stratum x is approximated by
EHSSx(m) ≈
{∑
t
n(m)(x, t)
}{x(0,(m))
∗x ((m)) − 1
}
, x = 0, 1. (7)
If the historical data is highly commensurate with the current trial data, there will be large gain in precision and a large
value for EHSSx(m) will result.
3.3 Response-adaptive randomization
We adapt the DBCD response-adaptive randomization scheme12 to incorporate borrowing from the historical control via
EHSSx(m) and only to adapt if the superiority of the intervention arm is supported. DBCD is an adaptive randomization
design constructed to target prespecified allocation proportions. With the probability of a successful recovery given by
𝜇x(t) in (2), we used the following allocation targets for the intervention group (t = 1) by the stroke strata:
𝜌x =
⎧⎪⎨⎪⎩
{𝜇x(t=1)}𝛾
{𝜇x(t=1)}𝛾+{𝜇x(t=0)}𝛾
for 𝛾 = 3∕4, if x = 0,
1−𝜇x(t=0)
1−𝜇x(t=1)+1−𝜇x(t=0)
, otherwise.
The targets were chosen based on the minimum effect size considered in the motivating example, that is, increasing the
response rates per stratum by 10% ormore. Themost common choice for the allocation target in the severe stroke stratum
(x = 0) is one with 𝛾 = 1∕2 but was not expected to yield the intended 10% or more increase.
We suppose that the mth subject ready for randomization is enrolled in the stratum x. The DBCD randomization
scheme12 assesses the proximity of the current sample proportion assigned to the intervention to the estimated target and
determines the allocation probability of assigning themth subject to the intervention arm using the following function:
𝜈
{
?̂?x(m), rx(m)
}
=
?̂?x(m)
(
?̂?x(m)
rx(m)
)𝜉
?̂?x(m)
(
?̂?x(m)
rx(m)
)𝜉
+ (1 − ?̂?x(m))
( (1−?̂?x(m))
(1−rx(m))
)𝜉 , (8)
where ?̂?x(m) and rx(m) denote the estimated allocation target and the current sample proportion assigned to the interven-
tion at the time, respectively. ?̂?x(m) was computed using the posterior means and 𝜉 = 2 was recommended in the work of
Rosenberger and Hu.29 We modified the computation of rx(m) to account for the additional information provided by the
historical control
rx(m) = {n(m)(x, t = 1)}∕
{∑
t
n(m)(x, t) + EHSSx(m)
}
.
Compared with no borrowing, the denominator increases by the borrowed historical control information, making rx(m)
smaller. If adaptive randomization is invoked, then the allocation probability to the intervention arm 𝜈{?̂?x(m), rx(m)} will
be more favorably skewed.
The proposed Bayesian design adapts the allocation probabilities selectively only if an evidence exists for the superiority
of the intervention arm. It has the following adaptive randomization scheme.
1. Enroll a total N∗ number of subjects across the strata using equal randomization within each stratum.
2. If P{𝜇x(t = 1) − 𝜇x(t = 0)) > 𝜂0} > 𝜁0 for some 0 < 𝜂0, 𝜁0 < 1, allocate each subject to the intervention arm adaptively
by the allocation probabilities given in (8). Otherwise, allocate equally between the treatment arms.
3. Conduct interim analyses when the total number of enrolled subjects across the strata reaches 50% or 75% of the
maximum sample size N. In the interims,
(a) stop for efficacy if P{𝜇x(t = 1) − 𝜇x(t = 0)) > 𝜂e} > 𝜁 e;
(b) stop for futility if P{𝜇x(t = 1) − 𝜇x(t = 0)) > 𝜂f} < 𝜁 f.
4. When the total number of enrolled subjects across the strata reaches the maximum sample size N, conduct the final
analysis. At the final analysis,
(a) conclude for efficacy if P{𝜇x(t = 1) − 𝜇x(t = 0)) > 𝜂e} > 𝜌e;
(b) conclude for futility if P{𝜇x(t = 1) − 𝜇x(t = 0)) > 𝜂f} < 𝜌f.
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𝜂0, 𝜂e, and 𝜂f are predetermined by clinically meaningful differences as illustrated in the motivating example later.
𝜁0, 𝜁 e, 𝜁 f, 𝜌e, and 𝜌f are tuning parameters. 𝜁0 is set to reduce the probability of assigning sizablymore subjects, for example,
10% of the enrolled subjects, to the inferior treatment arm. 𝜁 e and 𝜁 f can be set differently for each interim but to collec-
tively control the overall type I error rate and the overall type II error along with 𝜌e and 𝜌f at certain rates. More details of
determining the values of the tuning parameters are provided in the next section.
4 EMPIRICAL STUDIES
We used the motivating stroke trial data and designed simulation studies to evaluate the performance of the proposed
design. We assumed perfect commensurability and generated both the historical control and the concurrent trial data
in the same way: simulated data consist of observations (di,Xi,Zi,Ui, 𝛿i,Yi), where (di,Xi,Ui) were resampled from the
observed data and (Zi, 𝛿i,Yi) were generated from common outcome models. A subset of 182 subjects in the NINDS trial
met the eligibility criteria of the IMS III trial, and we simulated a sample of 182 for the historical control data. For the
current trial data, we simulated a sample ofN = 900 (600 for themoderate and 300 for the severe stratum, approximately).
We used one historical control data for all simulations conducted under the same parameter settings, whereas samples
for the current trial data were created each time.
4.1 Data generation and simulation setup
Each observation was generated sequentially by the following scheme, ie, for each 1 ≤ i ≤ N.
1. Sample values of stroke severity Xi and enrollment time di from the observed data were used.
2. For i ≤ 150, treatment assignments Ti were made at a 1:1 ratio within each stratum via block randomization. For
i > 150, Ti were determined by the proposed randomization scheme in Section 3.3.
3. Simulate Zi: Zi|Xi = x,Ti = t ∼ Bernoulli(𝛼(x, t)).
4. Simulate 𝛿i: 𝛿i|Xi = x,Ti = t,Zi = z ∼ Bernoulli(1 − S(u0 = 90|x, t, z)) with 1 − S(u0|x, t, z) = P(Ui < 90|x, t, z).
(a) If 𝛿i = 1, resample death time Ui.
(b) Otherwise, Ui = 90, and simulate Yi: Yi|Xi = x,Ti = t,Zi = z , 𝛿i = 0 ∼ Bernoulli(𝛽(x, t, z)).
The survival times greater than 90 days are arbitrarily censored since evaluation time is at 90 days. The observed 90 days
survival rates (P(𝛿i = 0)) differed by the short-term predictor but were similar between the treatment arms and across
the strata conditioning on the short-term predictor. We hence assumed S(u0 = 90|x, t, z) = S(u0 = 90|z) and resampled
observed death timeUi stratified by strata.We used piecewise exponential distributions tomodel S(u0 = 90|z) and logistic
regressions tomodel 𝛼(x, t) and 𝛽(x, z, t). The related parameterswere appropriately determined to equate 1− S(u0 = 90|z)
with the observed rates and attain the response rates specified in Table 1. The response rates assumed under the null were
based on the observed rates, whereas the ones assumed under the alternative were obtained by inflating the null rates to
yield 80% power given the maximum concurrent trial sample size. We refer to the Appendix for detailed specifications of
S(u0 = 90|x, t, z), 𝛼(x, t), 𝛽(x, z, t) and other details including the full conditional posterior distributions.
We first investigated the linearity assumption required for the approximated calculation of EHSS in (7). We simulated
1000 control group datasets under the null setting by varying the sample size from 100 through 1000 and computed
the posterior precision of 𝜇x(t = 0) based on 5000 Markov chain Monte Carlo (MCMC) iterations from the posterior
distribution in (5). The plot of the computed the posterior precision against the sample size shows that the purported
linear relationship with the sample size holds reasonably in order to allow the approximation (Figure 1).
We set 𝜂0 = 𝜂e = 10%. The 10% increase in the successful recovery was clinically meaningful in the stroke example
and was the minimum effect size sought after in the original trial. Similarly as the original trial, the futility of each
TABLE 1 Table of outcome model settings
Moderate Severe
H0 H1 H0 H1
T= 0 T= 1 T= 0 T= 1 T= 0 T= 1 T= 0 T= 1
Per stratum response rate 50% 50% 63% 17% 17% 31%
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FIGURE 1 Posterior precision of the control arm response rate as a function of sample size to test the linearity assumption
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FIGURE 2 Relationship between parameter values for triggering selective adaptive-randomization and difference in percent treated
simulation was assessed against no difference in the successful recovery and we set 𝜂f = 0. We then determined values
of the tuning parameters 𝜁0, 𝜁 e, 𝜁 f, 𝜌e, and 𝜌f via simulation. 𝜁0 is involved with selectively invoking the response-adaptive
randomization scheme using the probability P{𝜇x(t = 1)−𝜇x(t = 0)) > 10%}. A large value of 𝜁0 will reduce the likelihood
of assigning more subjects to the intervention arm even under the null, whereas it will reduce the number of subjects
assigned to the intervention under the alternative. This trade-off is illustrated in Figure 2. Based on this consideration, we
set 𝜁0 = 0.4. We conducted 5000 simulations each under the null and the alternative to determine the values of 𝜁 e, 𝜁 f, 𝜌e,
and 𝜌f in order to control the overall type I error rate at 5% and the type II error at 10%. The Bonferroni method was used
to control the overall error rates across the strata.
We used DBCD for the adaptive randomization for both borrowing and no borrowing. For the no-borrowing case, we
also considered equal randomization as a reference. The allocation probabilities were updated for a batch of every 10 and
20 new subjects in the severe and the moderate stratum, respectively, based on 500 MCMC iterations after 100 burn in.
This decision was made out of concern on computation time and resources. In contrast, the interim and final analyses
used 5000 MCMC iterations.
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FIGURE 3 Allocation probability to the intervention arm with accrual of patients by stratum
4.2 Simulation study results
The results presented in this section are based on 5000 Monte Carlo simulations each under the null and the alternative.
The allocation probabilities to the intervention arm averaged over the Monte Carlo simulation changed over the course
of the current trial adaptively to the underlying response rates (Figure 3). The proposed design is to selectively invoke the
response-adaptive randomization scheme only if the superiority of the intervention arm is supported. After a total of first
150 subjects equally allocated (∼ 50 in the severe and ∼100 in the moderate stratum), the allocation probabilities skewed
to favor the intervention arm under the alternative as more subjects got enrolled. The probabilities were more heavily
skewed with borrowing on the control from the historical data than without borrowing. The trend persisted throughout
the trial. Under the null, the allocation probabilities initially skewed to favor the intervention arm but changed back to
0.5 as more subjects enrolled and the criterion invoking selective adaptive randomization got more reliably assessed. The
allocation probabilities changed less stably with borrowing on the control arm. This is because the commensurability
with the historical sample changed from simulation to simulation, although perfect commensurability was assumed.
Table 2 summarizes the operating characteristics of the proposed design with borrowing and no borrowing and those of
equal randomizationwhen each designwas calibrated to have the same type I and type II errors. Borrowing on the control
improved operating characteristics of the response-adaptive design. Under the alternative borrowing increased the power
from 81.52% to 90.36% in the moderate stroke stratum and 61.62% to 77.16% in the severe stroke stratum. It also enabled
the design to stop early correctly more frequently. The percentage that stopped early correctly under the alternative with
and without borrowing is noticeably different in the severe stroke stratum specifically (69.52 versus 27.52). The informa-
tion borrowed from the historical data consequently led to reduction in the sample size and trial duration. Under H1, on
average 63 or 25% less subjects were enrolled in the severe stroke arm with borrowing, which is anticipated to reduce the
trial duration by 637 days based on the real trial enrollment data. In themoderate stroke arm, 45 or 11% less were enrolled,
which is anticipated to reduce the trial duration by 192 days. Under the alternative, more subjects were treated with the
intervention and observed response rates were higher with borrowing. The benefits were more pronounced when com-
pared with equal randomization fixed designs with no borrowing. Whether to borrow or not, with the response-adaptive
design the observed response rates were higher (27.55% and 26.07% versus 24.41% in the severe stroke stratum, 58.52%
and 58.35% versus 57.34% in the moderate stroke stratum). Without borrowing, it is known that the responsive adap-
tive randomization may have lower power than equal randomization, since the goal of treating more patients with better
treatment may conflict with the goal of maximizing power. That was clearly the case in the severe stroke stratum. The
percentage of correctly stopping early was also lower (27.52% vs 58.62%), and hence, the adaptive randomization required
the larger sample on average (256.31 vs 210.80) under the alternative. Borrowing on the control, however, offsets such
compromises, even increasing power and reducing the sample size compared with equal randomization.
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TABLE 2 Table of operating characteristics
Severe Stroke Stratum
H0 H1
Borrowing No Borrowing Borrowing No Borrowing
AR AR ER AR AR ER
Power 1.26 1.26 1.26 77.16 61.62 78.16
% Early stopped correctly 83.56 82.52 83.36 69.52 27.52 58.62
% Early stopped wrongfully 0.94 0.94 0.94 7.04 7.02 7.04
% Successful recovered (SD) 16.20 (3.51) 16.98 (2.87) 16.98 (2.94) 27.55 (3.66) 26.07 (2.91) 24.41 (3.07)
Average sample size 180.33 183.57 181.42 192.91 256.31 210.80
Moderate Stroke Stratum
H0 H1
Borrowing No Borrowing Borrowing No Borrowing
AR AR ER AR AR ER
Power 1.04 1.04 1.04 90.36 81.52 81.46
% Early stopped correctly 94.74 91.94 90.80 79.14 69.16 70.48
% Early stopped wrongfully 0.92 0.92 0.92 7.00 7.00 7.00
% Successful recovered (SD) 50.26 (2.41) 50.20 (2.75) 50.21 (2.75) 58.52 (2.83) 58.35 (2.56) 57.34 (2.49)
Average sample size 324.61 341.67 346.21 365.05 409.66 410.03
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FIGURE 4 Percent treated with intervention by stratum with and without borrowing
We computed the observed treatment allocations by strata in each simulation in order to further examine whether
the purported advantage of the response-adaptive design was better realized by the proposed design with borrowing on
the control arm (Figure 4). Interim analyses concluded to stop early in some simulations and the observed treatment
allocations were normalized as percentages over the per stratum enrolled sample sizes. Borrowing on the control led to
assigning many more subjects to the intervention arm under the alternative. On average, 69.2% and 60.2% subjects were
assigned to the intervention in the severe and the moderate stratum respectively with borrowing on the control. These
were higher than the observed averages of 62.3% and 57.4% obtained via response-adaptive randomization alone without
borrowing. In order for the response-adaptive design alone to target similarly higher proportions of intervention treated
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subjects without borrowing, the true response rates needed to be as high as 50.0% in the severe stratum and 66.9% in the
moderate stratum as opposed to 31% and 63% assumed here. Under the null, the proposed design performed similarly
whether to borrow or not. As the design adapted the allocation rates only selectively if the superiority of the intervention
is supported at the time of assessment, on average more than 50% subjects were treated with the intervention but only to
modest degree.
In the moderate stroke stratum, the expected response rate under equal randomization is 56.6%, whereas the average
observed rates were 58.52% with borrowing and 58.35% without borrowing. In the severe stroke stratum, the expected
response rate is 24.0% with equal randomization, whereas the average observed rates were 27.55% with borrowing and
26.07% without borrowing. The distributions of observed successful recovery rates are available in Figure S3 of the
Supplemental Material. Compared with the expected response rate under equal randomization, in the moderate stroke
stratum on average, ∼2 more subjects for every 100 subjects would recover from stroke with no or little disability. This
amounts to ∼12 more subjects with desirable outcomes if the maximum target would be enrolled. In the severe stroke
stratum on average, 3∼4 more subjects borrowing and 2more without borrowing for every 100 subjects would have desir-
able outcomes. Since a nonsuccessful recovery is death or a significant disability throughout the rest of a patient's life,
the observed increase in the percentage of a successful recovery is meaningful with or without borrowing. The additional
increase with borrowing was modest in both strata since it corresponds to the difference in the response rate between the
treatment arms realized in the subjects additionally treated with the intervention with borrowing. Suppose a case that
10% more patients were assigned to the intervention arm in the severe stratum. The increase in the number treated with
the intervention leads to increase in the successful recovery rate only by 1.4%, as not all 10% but its fraction that would not
have recovered successfully if had treated by the control arm only contributes to the increase in the successful recovery
rate: 10% × (0.31 − 0.17) = 1.4%.
Borrowing on the control also increased the total amount of information and led to better precision. With the selective
randomization adaptation, we anticipate borrowing on the control would lead to a better precision only in the control arm
under the null, whereas it would improve the precision in the intervention arm under the alternative. The posterior stan-
dard error of the successful recovery rate observed in the severe stratum by treatment arm with and without borrowing
in Figure 5 supports this conjecture partially. Under the null the posterior standard error of the successful recovery rate
was smaller with borrowing in both treatment arms. Under the alternative, the posterior standard error was smaller with
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FIGURE 5 Standard error of successful recovery rate with and without borrowing by treatment arm
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borrowing in the intervention arm but not in the control arm. The slightly larger control group standard error may be due
to varying commensurability from sample to sample. Although perfect commensurability was assumed, the commensu-
rability with the historical sample changed from simulation to simulation. Similar results were observed in the moderate
stratum (Figure S4 in the Supplemental Material).
The EHSS has been summarized in Figure S2 of the Supplemental Material. The EHSS in the severe stroke stratum
under H1 is much larger than that under H0. However, the EHSS in the moderate stroke stratum is similar under H1
and H0. This is because the EHSS quantifies relative gain in the posterior precision due to borrowing from the historical
control and is related to the relative size of the historical control sample to the current trial control sample. The much
smaller current trial control sample under H1 than H0 in the severe stroke arm (on average 30.8% vs 47.5% treated with
the control) made the impact of the historical control much greater and consequently the EHSS larger under H1. In the
moderate stroke arm, the difference was smaller (39.8% versus 48.2%) and the first ∼100 patients equally allocated made
the impact of the historical control data similar under H1 and H0.
5 CONCLUSION
In this paper, we propose a Bayesian design that is adaptive both in incorporating historical control data and to the relative
treatment effects. This proposal differs from the existing work on borrowing on the control group from historical data. As
opposed to reducing the number of subjects assigned to the control group regardless of the true relative effects, we aim to
reduce the current control group sample size adaptively to the true response rates and also only if the intervention arm is
superior. This required modifying existing response-adaptive randomization schemes to selectively adapt the allocation
ratios only when evaluation of cumulated current trial data combined with the historical control suggests the superiority
of the intervention arm and to account for information borrowed from the historical control as well. We used the EHSS
approach10 and modified the response-adaptive randomization scheme of the DBCD12 to incorporate EHSS in determin-
ing the allocation probabilities adaptively to the response. The modified response-adaptive randomization scheme was
incorporated in a Bayesian design with commensurate priors.
The primary limitation of using historical controls is changes in standard of practice of care. Other priors that
address the potential conflict such as meta-analytic-predictive priors11 exist and can be used instead. Similarly, other
response-adaptive randomization schemes can be used if they can be appropriately modified. Only binary outcomes were
considered here but the proposed design can be readily modified for other outcome types. Valid high quality historical
control data need to exist for the proposed design. As shown in the motivating stroke example, data from a historical trial
similarly conducted in the same subject population with similar study design is not uncommon. With such high quality
historical data existing, as compared with no borrowing, the proposed response-adaptive design with borrowing on the
control arm treatedmore subjects with the intervention arm and wasmore likely to early conclude in line with the under-
lying truth with better precision, even accommodating early stopping by interim analyses. The additional improvement
in the subjects' outcomes brought by borrowing, however, was modest for treatment differences commonly observed in
practice as shown in the motivating stroke example. As borrowing on the historical control does not add logistical burden
in the implementation, the additional improvement, albeit modest, is worthy in clinical settings where a nonfavorable
outcome is death or involves significant life-long burdens.
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APPENDIX
Data simulation and estimation
R script files containing codes can be downloaded as supplemental materials. For data simulation, we assume the
following models:
log
{
𝛼(xi, ti)
1 − 𝛼∗(xi, ti)
}
=a0 + a1xi + a2ti + a3xiti
log h(u|z) ={log 𝜆1 + 𝛾2z, for u < 14
log 𝜆2 + 𝛾2z, otherwise
log
{
𝛽(xi, zi, ti)
1 − 𝛽∗(xi, zi, ti)
}
=b0 + b1xi + b2zi + b3ti + b4tixi .
The value of the coefficient b2 determines the association between the short-term outcome and the long-term outcome.
We used b2 = 2.4014, which introduced association measured by 𝜙 coefficient30 ranging 0.26 ∼ 0.61 in the severe stratum
and 0.42 ∼ 0.64 in the moderate stratum under different scenarios. The observed 90 days survival rates differed by the
short-term predictor but were similar between the treatment arms and across the strata conditioning on the short-term
predictor. The parameters were appropriately determined to equate 1 − S(u0 = 90|z) with the observed rates and attain
the response rates specified in Table 1.
Priors
Let 𝜽 = (a0, a1, a2, a3, log 𝜆1, log 𝜆2, 𝛾2, b0, b1, b2, b3, b4) be the vector of current parameters and the corresponding vector
of historical parameters be 𝜽0 = (a00, a01, log 𝜆01, log 𝜆02, 𝛾02, b00, b01, b02). We assume a noninformative or vague prior,
N(0, 1∕w), for the parameters involved with treatment effects in the current data, that is, (a2, a3, b3, b4). Similarly, we
assume a noninformative prior for all components in 𝜽0, that is, 𝜃0l ∼ N(0, 1∕w). We assume w = 100 for the noninfor-
mative priors. Given historical data 0 on the control group, we assume the following commensurate prior for all other
parameters in 𝜽:
𝜃l ∼ N(𝜃0l, 1∕𝜏l),
where 𝜏 l, l = 1, … , 𝜈 has uniform distribution over the support [𝜔a, 𝜔b] and a point probability distribution at 𝜔c for
some 𝜔c > 𝜔b such that {
P(𝜏l < 𝜅) = 𝜅−𝜔a
𝜔b−𝜔a
for 𝜔a < 𝜅 < 𝜔bwith the probability𝜔d,
P(𝜏l = 𝜔c) = 1 − 𝜔d for 𝜔c > 𝜔b.
It has been shown that themarginalized likelihood of the data is flat over a vast portion of the parameter space but prefers
a large value for 𝜏 l when there is little evidence for heterogeneity.9 Thus, smaller values of 𝜔b and large values of 𝜔c
will impose more borrowing.9,10 Following this recommendation, we set 𝜔a = .01, 𝜔b = 10, and 𝜔c = 5000. An equal
probability is assigned to the spike and the slab, that is, 𝜔d = .5.
Posterior distributions
Posterior distributions using the current trial data only
The full conditional log posterior distributions of the parameters are as follows.
1. log(al) ∝
∑n
i=1 zi(a0 + a1xi + a2ti + a3xiti) −
∑n
i=1 log[1 + exp(a0 + a1xi + a2ti + a3xiti)] − wa2l ∕2.
2. log(bl) ∝
∑n
i=1(1−𝛿i(m))𝑦i(b0+b1xi+b2zi+b3ti+b4xiti)−
∑n
i=1(1−𝛿i(m)) log[1+exp(b0+b1xi+b2zi+b3ti+b4xiti)]−wb2l ∕2.
3. log(𝛾2) ∝
∑n
i=1 𝛿i(m)(𝛾2zi) −
∑n
i=1(exp(log(𝜆1))I[ui(m)<14]ui(m) + exp(log(𝜆2))I[ui(m)>14](ui(m) − 14) + 14 exp(log(𝜆1))
I[ui(m)>14]) exp(𝛾2zi) − w𝛾22∕2.
4. log(log(𝜆l)) ∝
∑n
i=1 𝛿i(m)(exp(log(𝜆1))I[ui(m)<14]+exp(log(𝜆2))I[ui(m)>14])−
∑n
i=1(exp(log(𝜆1))I[ui(m)<14]ui(m)+exp(log(𝜆2))
I[ui(m)>14](ui(m) − 14) + 14 exp(log(𝜆1))I[ui(m)>14]) exp(𝛾2zi) − w log (𝜆l)2∕2.
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Posterior distributions using both the current trial data and historical control data
The full conditional log posterior distributions of the parameters are as follows.
1. log(al) ∝
∑n
i=1 zi(a0 + a1xi + a2ti + a3xiti) −
∑n
i=1 log[1 + exp(a0 + a1xi + a2ti + a3xiti)] − 𝜏al(al − a0l)2∕2; l = 0, 1.
2. log(a0l) ∝
∑n0
i=1 z0i(a00 + a01x0i) −
∑n0
i=1 log[1 + exp(a00 + a01x0i)] − wa
2
0l∕2 − 𝜏al(al − a0l)
2∕2; l = 0, 1.
3. log(al) ∝
∑n
i=1 zi(a0 + a1xi + a2ti + a3xiti) −
∑n
i=1 log[1 + exp(a0 + a1xi + a2ti + a3xiti)] − wa2l ∕2; l = 2, 3.
4. log(bl) ∝
∑n
i=1(1− 𝛿i(m))𝑦i(b0+ b1xi+ b2zi+ b3ti+ b4xiti)−
∑n
i=1(1− 𝛿i(m)) log[1+ exp(b0+ b1xi+ b2zi+ b3ti+ b4xiti)]−
wb2l ∕2 − 𝜏bl(bl − b0l)
2∕2; l = 0, 1, 2.
5. log(b0l) ∝
∑n0
i=1(1−𝛿0i)𝑦0i(b00+b01x0i+b02z0i)−
∑n0
i=1(1−𝛿0i) log[1+exp(b00+b01z0i+b02z0i)]−wb
2
0l∕2−𝜏bl (bl − b0l)
2∕2;
l = 0, 1, 2.
6. log(bl) ∝
∑n
i=1(1−𝛿i(m))𝑦i(b0+b1xi+b2zi+b3ti+b4xiti)−
∑n
i=1(1−𝛿i(m)) log[1+exp(b0+b1xi+b2zi+b3ti+b4xiti)]−wb2l ∕2;
l = 3, 4.
7. log(𝛾2) ∝
∑n
i=1 𝛿i(m)(𝛾2zi) −
∑n
i=1(exp(log(𝜆1))I[ui(m)<14]ui(m) + exp(log(𝜆2))I[ui(m)>14](ui(m) − 14) + 14 exp(log(𝜆1))
I[ui(m)>14]) exp(𝛾2zi) − 𝜏𝛾2(𝛾2 − 𝛾02)2∕2.
8. log(𝛾02) ∝
∑n0
i=1 𝛿0i(𝛾02z0i) −
∑n0
i=1(exp(log(𝜆01))I[u0i<14]u0i + exp(log(𝜆02))I[u0i>14](u0i − 14) + 14 exp(log(𝜆01))I[u0i>14])
exp(𝛾02z0i) − 𝜏𝛾02(𝛾02 − 𝛾02)2∕2 − w𝛾202∕2.
9. log(log(𝜆l)) ∝
∑n
i=1(1 − 𝛿i(m))(log(𝜆1))I[ui(m)<14] + log(𝜆2))I[ui(m)>14]) −
∑n
i=1(exp(log(𝜆1))I[ui(m)<14]ui(m) + exp(log(𝜆2))
I[ui(m)>14](ui(m) − 14) + 14 exp(log(𝜆1))I[ui(m)>14]) exp(𝛾2zi) − 𝜏𝜆l (log(𝜆l) − log(𝜆0l))2∕2; l = 1, 2.
10. log(log(𝜆0l)) ∝
∑n0
i=1(1 − 𝛿0i)(log(𝜆01))I[u0i<14] + log(𝜆02))I[u0i>14]) −
∑n0
i=1(exp(log(𝜆01))I[u0i<14]u0i + exp(log(𝜆02))I[u0i>14]
(u0i − 14) + 14 exp(log(𝜆01))I[u0i>14]) exp(𝛾02z0i) − 𝜏𝜆l (log(𝜆l) − log(𝜆0l))2∕2 − w log (𝜆0l)2∕2; l = 0, 1.
11. log(𝜏l) ∝
{
log(𝜏l)∕2 − 𝜏l(𝜃l − 𝜃0l)2∕2 + log(𝜏l − 𝜔a), for 𝜔a ≤ 𝜏l ≤ 𝜔b, and
log(𝜏l)∕2 − 𝜏l(𝜃l − 𝜃0l)2∕2, for 𝜏l = 𝜔c.
Let, q(𝜏 l) be the posterior distribution of 𝜏 l. Then, 𝜔∗d =
𝜔∗a
𝜔∗a+𝜔
∗
b
is the posterior probability for 𝜔a ≤ 𝜏 l ≤ 𝜔b, where
𝜔∗a = 𝜔d ∫ 𝜔b𝜔a q(𝜏l)d𝜏l, and 𝜔∗b = (1 − 𝜔d)q(𝜏l).
